【レポートの概要（一部）】
1. Report Overview
1.1 Introduction to the Diabetes Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered by This Study
1.7 Who is This Study For?
1.8 Research Methods and Analysis
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Global Diabetes Drugs Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified?
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2016-2026
3.1 The World Diabetes Drug Market, 2015
3.1.1 Diabetes Treatment Market by Drug Class, 2015
3.1.2 Top Selling Diabetes Drugs, 2015
3.1.3 Generic Anti-Diabetes Drugs, 2015
3.2 World Diabetes Drugs Market: Revenue Forecast, 2016-2026
3.3 Injectable and Non-injectable Diabetes Drugs, 2016-2026
3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2016-2026
3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2016-2026
4. Human Insulin and Analogues, 2016-2026
4.1 Insulin and Insulin Analogues Drugs, 2015
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2016-2026
4.3 Insulin and Insulin Analogues: Market Trends, 2016-2026
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2016-2026
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2016-2026
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2016-2026
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2016-2026
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2016-2026
5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2016-2026
5.1 DPP-4 Market, 2015
5.2 DPP-4 Inhibitors Revenue Forecast, 2016-2026
5.3 Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2016-2026
5.4 Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2016-2026
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2016-2026
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2016-2026
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2016-2026
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2016-2026
6. Sulfonylureas Market, 2016-2026
6.1 Sulfonylureas Market, 2015
6.2 Sulfonylureas: Revenue Forecast 2016-2026
6.3 Sulfonylureas: Market Trends 2016-2026
6.3.1 New Opportunites for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2016-2026
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2016-2026
6.6 Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2016-2026
7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2016-2026
7.1 GLP-1 Receptor agonists Market, 2015
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2016-2026
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2016-2026
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2016-2026
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
8. Alpha-glucosidase Inhibitors Market, 2016-2026
8.1 Alpha-glucosidase Inhibitors Market, 2015
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2016-2026
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2016-2026
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2016-2026
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2016-2026
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2016-2026
9. Meglitinides Market, 2016-2026
9.1 Meglitinides Market, 2015
9.2 Meglitinides: Revenue Forecast, 2016-2026
9.2.1 Meglitinides: Market Trends, 2016-2026
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2016-2026
9.4 Starlix (Nateglinide; Novartis): Revenue Forecast, 2016-2026
9.5 Glufast (Acarbose; Eisai): Revenue Forecast, 2016-2026
10. Thiazolidinediones Market, 2015
11. Sodium – glucose Co-transporter (SGLT2) Inhibitors Market, 2016-2026
11.1 SGLT2 Inhibitors Market, 2015
11.2 SGLT2 Revenue Forecast, 2016-2026
11.2.1 SGLT2 Market Trends, 2016-2026
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2016-2026
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2016-2026
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2016-2026
12. Biguanides Market, 2016-2026
12.1 Biguanides Market, 2015
12.2 Biguanides: Revenue Forecast: 2016-2026
12.2.1 Biguanides: Market trends, 2016-2026
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2016-2026
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2016-2026
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2016-2026
13. National Markets for Diabetes Drugs, 2016-2026
13.1 Leading National Markets for Diabetes Drugs, 2015
13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2016-2026
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2016-2026
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast, 2016-2026
13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.2 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2015
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2016-2026
13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2016-2026
13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval?
13.5.3 French National Diabetes Market Revenue Forecast, 2016-2026
13.5.3.1 Great Standard of Care and Regulatory Reforms in France
13.5.4 The UK National Diabetes Market Revenue Forecast, 2016-2026
13.5.4.1 Faster Approvals for New Therapies in the UK
13.5.5 Italian National Diabetes Market Revenue Forecast, 2016-2026
13.5.6 Spanish National Diabetes Market Revenue Forecast, 2016-2026
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2016-2026
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2016-2026
13.7.1 Focus on the Rural Population
13.8 The Russian National Diabetes Market, 2016-2026
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2016-2026
13.9.1 Localised Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2016
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
14.3.3 NN9924 (Novo Nordisk)
14.3.4 BIOD-123 (Biodel)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck (MSD))
14.5 GLP-1: New Approvals and Pipeline, 2016
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
14.5.2 Semaglutide (NN9535; Novo Nordisk)
14.5.3 Xultophy (IdegLira; Novo Nordisk)
14.5.4 ITCA 650 (Intarcia Theraputics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
14.6.1 Sotagliflozin (Lexicon Pharmacuticals)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 MK8835 (Ertugliflozin; Merck (MSD))
14.6.4 Bexagliflozin (Theracos)
14.7 Other Diabetes Drugs: Pipeline Developments, 2016
14.7.1 DM199 (DiaMedica)
14.7.2 Glucokinase Activators
14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2016-2026
15.1 SWOT Analysis of the Diabetes Drug Market, 2016-2026
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2016-2026
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues
16. Research Interviews
16.1 Interview with Professor Mark Baker, Clinical Practice Director of the National Institute of Healthcare Excellence (NICE)
17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2016-2026
17.3 Insulin Will Continue to Dominate the Market
17.4 National Diabetes Market Outlooks, 2016-2026
17.5 Future Opportunities
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：糖尿病治療薬の世界市場2016-2026■ 英文：Diabetes World Drug Market Report 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60707
■ 調査対象地域：グローバル
- 無菌包装の世界市場2017-2021About Aseptic Packaging Aseptic packaging is the packaging of products in the aseptic environment in pre-sterilized containers, to prevent the products from contamination and maintain freshness for a long period of time. Aseptic packaging involves flash pasteurization of products to retain their original aroma, texture, and organoleptic characteristics and contains no preservatives or additives. T …
- 世界のテレビ及びビデオサービス市場Our TV experts publish half-yearly their TV & Video Services observatory, covering 37 countries, 10 regions and world consolidated. This ongoing monitoring is accompanied by regular analyses and analyst viewpoints of trends, disruptions and industry
- 自動車用歯車の世界市場：遊星歯車、かさ歯車、ラック・アンド・ピニオン、ハイポイドギヤ、ウォームギヤ、ヘリカルギヤ、平歯車The global automotive gears market is projected to grow at a CAGR of 6.1% from 2015 to 2020. The market is estimated to be USD 28.47 Billion in 2015 and is projected to reach 38.27 Billion by 2020. Asia-Pacific is the largest market for automotive gears, followed by North America and Europe. The growth of the automotive gears market is fueled by increasing vehicle production, enhanced driving expe …
- 2014年戦略提言：アメリカの薬物乱用ポイントオブケア（POC）検査市場This new 165-page report from Venture Planning Group contains 14 tables, and provides a comprehensive analysis of the POC drugs of abuse testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop eff …
- 北米の睡眠時無呼吸診断装置市場North America Sleep Apnea Diagnostic Systems Market Outlook to 2021 Summary GlobalData’s new report, "North America Sleep Apnea Diagnostic Systems Market Outlook to 2021", provides key market data on the North America Sleep Apnea Diagnostic Systems market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments Fixed Po …
- ケーブルトレイの世界市場2017-2021About Cable TrayA cable tray is a subset of cable management systems. Cable trays are used to provide mechanical support and protection to electrical cables or wires that are used for power distribution and data communication within a building. They can support various types of wires — high-voltage power lines, power distribution cables, sensitive control wiring, telecommunication wiring, and opti …
- デジタルマップの世界市場2016-2020About Digital Mapping Digital mapping is a process in which a collection of data is compiled to produce maps, in the form of virtual images, which accurately represent a particular geographical area, the major roads, rivers, and important landmarks such as airports, tourist attractions, and hospitals in and around the region. Digital mapping technology can also be used to calculate distances betwe …
- リグニンの世界市場分析：製品別（リグノスルホン酸塩、クラフトリグニン、オルガノソルブリグニン）、用途別（巨大分子、芳香）、地域別（北アメリカ、ヨーロッパ、APAC、中南米、MEA）、セグメント予測、2014-2025The global lignin market is expected to reach USD 913.1 million by 2025, according to a new report by Grand View Research, Inc. The growing environmental concerns regarding air pollution and associated health hazards have been the major factors driving market growth. The growing demand for dust control in residential, commercial, and industrial sectors is expected drive growth further over the for …
- 冷凍パン類製品の世界市場予測（～2022）：種類別（パン、ピザクラスト、ケーキ＆ペーストリー）、販売チャンネル別、技術別An excellent growth has been recorded in the global frozen bakery products market over the last couple of decades. The market size is projected to reach USD 23.48 Billion by 2022, at a CAGR of around 7.9% from 2016. Increase in demand for convenient food products and drive for greater taste, safety, and consistency are the major factors driving the global frozen bakery products market. Emerging co …
- Concentrated Photovoltaic (CPV), 2012 – Global Market Size, Average Installation Price, Market Share, Regulations and Key Country Analysis to 2020Concentrated Photovoltaic (CPV), 2012 - Global Market Size, Average Installation Price, Market Share, Regulations and Key Country Analysis to 2020 Summary “Concentrated Photovoltaic (CPV), 2012 - Global Market Size, Average Installation Price, Market Share, Regulations and Key Country Analysis to 2020” is an alternative energy offering from GlobalData that offer comprehensive information and under …
- 世界におけるコネクティッド・カーのエコシステム：市場機会、課題、戦略、予測The growing proliferation of embedded in-vehicle connectivity and smartphone integration platforms has made connected cars one of the fastest growing segments of the IoT (Internet of Things) market. Keen to establish recurring post-sale service revenue streams, all major automotive OEMs are investing in connected car programs. Other ecosystem players, such as mobile operators and telematics specia …
- 世界主要国におけるCA腫瘍マーカー検査市場2015This report contains 278 pages, 40 tables and presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.The c …
- 性能添加剤の世界市場予測（～2021年）：プラスチック添加剤、塗料添加剤、顔料添加剤、インク添加剤“Growing use in packaging and household goods industries is a prime factor for the growth of the performance additives market”The global performance additives market is projected to reach USD 110.35 billion by 2021, at a CAGR of 8.0%, in terms of value. This growth can be attributed in parts to the rising investments in new manufacturing plants for packaging in various countries. This growth also …
- 神経血管ステントの世界市場2017-2021ABSTRACTAbout Neurovascular Stents A neurovascular stent is a small, flexible, tube-like device made of fabric supported by a metal mesh. It is used to treat several conditions in the brain such as stenosis formation in the blood vessels and ischemic stroke, and aneurysm. Neurovascular stents are segmented into two types based on product types such as carotid artery stents and intracranial stents. …
- ポリマーフォーム（発泡体）の世界市場予測（～2022年）：PU、PS、PO、PVC、フェノール、メラミンPolyolefin foam (PO) is the fastest-growing type of polymer foamThe market size of polymer foam was estimated at USD 94.86 billion in 2017 and is projected to reach USD 126.08 billion by 2022, at a CAGR of 5.86% from 2017 to 2022. PO is the fastest-growing type of polymer foam because of its resilience. It is an excellent energy absorber, making it useful in cushion packaging, athletic pads, float …
